Showing results (571-580 of 622) with videos related to

Sort By:
Pageof 63
Malaria Journal|July 19, 2019
Prevalence of submicroscopic malaria infection in immigrants living in SpainIsabel Fradejas, José Miguel Rubio, Ariadna Martín-Díaz, et al.
Lancet (London, England)|April 6, 2024
3-year invasive disease-free survival with chemotherapy de-escalation using an <sup>18</sup>F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trialJosé Manuel Pérez-García, Javier Cortés, Manuel Ruiz-Borrego, et al.
Trends in Ecology & Evolution|February 2, 2019
Extreme Competence: Keystone Hosts of InfectionsLynn B Martin, BriAnne Addison, Andrew G D Bean, et al.
BMC Public Health|July 29, 2008
Predicting the onset and persistence of episodes of depression in primary health care. The predictD-Spain study: methodologyJuan Angel Bellón, Berta Moreno-Küstner, Francisco Torres-González, et al.
The New England Journal of Medicine|March 20, 2024
Ribociclib plus Endocrine Therapy in Early Breast CancerDennis Slamon, Oleg Lipatov, Zbigniew Nowecki, et al.
The New England Journal of Medicine|December 3, 2010
Adjuvant docetaxel for high-risk, node-negative breast cancerMiguel Martín, Miguel A Seguí, Antonio Antón, et al.
Clinical and Experimental Rheumatology|October 6, 2017
Clinical and epidemiological differences between men and women with systemic sclerosis: a study in a Spanish systemic sclerosis cohort and literature reviewMayka Freire, Alberto Rivera, Bernardo Sopeña, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|September 19, 2018
Prognostic Factors of Death in 151 Adults With Hemophagocytic Syndrome: Etiopathogenically Driven AnalysisPilar Brito-Zerón, Belchin Kostov, Pedro Moral-Moral, et al.
Clinical Breast Cancer|November 13, 2020
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET TrialArlene Chan, Beverly Moy, Janine Mansi, et al.
Eclinicalmedicine|April 19, 2024
Preventing alpelisib-related hyperglycaemia in HR+/HER2-/<i>PIK3CA</i>-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trialAntonio Llombart-Cussac, José Manuel Pérez-Garcia, Manuel Ruiz Borrego, et al.
Pageof 63